Immunomedics, Inc. (NASDAQ:IMMU) reported Q4 2017 earnings this Afternoon, coming in at ($0.48) per share, missing Wall Street’s estimates of ($0.12) per Share. Revenue for the quarter came in at $0.64 million missing the streets estimates of $0.75 million
Analyst Coverage For Immunomedics, Inc. (NASDAQ:IMMU)
These are 3 Buy Ratings .
The current consensus rating for Immunomedics, Inc. (NASDAQ:IMMU) is Buy (Score: 3.00) with a consensus target price of $13.00 , a potential (67.10% upside)Recent Insider Trading for Immunomedics, Inc. (NASDAQ:IMMU)
- On 8/24/2016 Don C Stark, Director, sold 9,900 with an average share price of $2.97 per share and the total transaction amounting to $29,403.00.
- On 8/23/2016 Mary E Paetzold, Director, sold 15,000 with an average share price of $2.98 per share and the total transaction amounting to $44,700.00.
- On 6/13/2016 Cynthia L Goldenberg, CEO, sold 371,990 with an average share price of $3.03 per share and the total transaction amounting to $1,127,129.70.
- On 6/8/2016 Cynthia L Goldenberg, CEO, sold 41,441 with an average share price of $3.62 per share and the total transaction amounting to $150,016.42.
- On 6/8/2016 David M Goldenberg, Chairman, sold 353,010 with an average share price of $3.88 per share and the total transaction amounting to $1,369,678.80.
- On 6/7/2016 Cynthia L Goldenberg, CEO, sold 4,600 with an average share price of $4.01 per share and the total transaction amounting to $18,446.00.
Recent Trading for Immunomedics, Inc. (NASDAQ:IMMU) Shares of Immunomedics, Inc. closed the previous trading session at 7.78 down -0.26 -3.23% with 2,122,811 shares trading hands.